These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35145310)

  • 1. A solid start for gene therapy in Tay-Sachs disease.
    Yu TW; Bodamer O
    Nat Med; 2022 Feb; 28(2):236-237. PubMed ID: 35145310
    [No Abstract]   [Full Text] [Related]  

  • 2. Towards gene therapy for Tay-Sachs disease.
    Clyde D
    Nat Rev Genet; 2022 Apr; 23(4):197. PubMed ID: 35194181
    [No Abstract]   [Full Text] [Related]  

  • 3. Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Lynch A; Ziegler R; Cheng SH; Cox TM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10373-10378. PubMed ID: 16801539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future perspectives for Tay-Sachs disease.
    Desnick RJ; Kaback MM
    Adv Genet; 2001; 44():349-56. PubMed ID: 11596996
    [No Abstract]   [Full Text] [Related]  

  • 5. Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease.
    Vu M; Li R; Baskfield A; Lu B; Farkhondeh A; Gorshkov K; Motabar O; Beers J; Chen G; Zou J; Espejo-Mojica AJ; Rodríguez-López A; Alméciga-Díaz CJ; Barrera LA; Jiang X; Ory DS; Marugan JJ; Zheng W
    Orphanet J Rare Dis; 2018 Sep; 13(1):152. PubMed ID: 30220252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-onset Tay-Sachs disease.
    Neudorfer O; Kolodny EH
    Isr Med Assoc J; 2004 Feb; 6(2):107-11. PubMed ID: 14986470
    [No Abstract]   [Full Text] [Related]  

  • 7. Tay-Sachs disease: from clinical description to molecular defect.
    Kaback MM; Desnick RJ
    Adv Genet; 2001; 44():1-9. PubMed ID: 11596975
    [No Abstract]   [Full Text] [Related]  

  • 8. Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease.
    Gray-Edwards HL; Randle AN; Maitland SA; Benatti HR; Hubbard SM; Canning PF; Vogel MB; Brunson BL; Hwang M; Ellis LE; Bradbury AM; Gentry AS; Taylor AR; Wooldridge AA; Wilhite DR; Winter RL; Whitlock BK; Johnson JA; Holland M; Salibi N; Beyers RJ; Sartin JL; Denney TS; Cox NR; Sena-Esteves M; Martin DR
    Hum Gene Ther; 2018 Mar; 29(3):312-326. PubMed ID: 28922945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical Issues with Genetic Testing for Tay-Sachs.
    Clayton T
    J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating Immune Responses to the scAAV9-
    Kot S; Karumuthil-Melethil S; Woodley E; Zaric V; Thompson P; Chen Z; Lykken E; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.
    Hussein N; Weng SF; Kai J; Kleijnen J; Qureshi N
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010849. PubMed ID: 26264938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells.
    Igdoura SA; Mertineit C; Trasler JM; Gravel RA
    Hum Mol Genet; 1999 Jun; 8(6):1111-6. PubMed ID: 10332044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tay-Sachs disease].
    Tanaka A
    Nihon Rinsho; 1993 Sep; 51(9):2281-5. PubMed ID: 8411703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal transcription of the beta-hexosaminidase alpha-chain gene in the Ashkenazi Tay-Sachs mutation.
    Paw BH; Neufeld EF
    J Biol Chem; 1988 Feb; 263(6):3012-5. PubMed ID: 2449434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene.
    Myerowitz R
    Hum Mutat; 1997; 9(3):195-208. PubMed ID: 9090523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural consequences of amino acid substitutions causing Tay-Sachs disease.
    Ohno K; Saito S; Sugawara K; Sakuraba H
    Mol Genet Metab; 2008 Aug; 94(4):462-468. PubMed ID: 18490185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
    Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
    Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemistry and genetics of Tay-Sachs disease.
    Gravel RA; Triggs-Raine BL; Mahuran DJ
    Can J Neurol Sci; 1991 Aug; 18(3 Suppl):419-23. PubMed ID: 1834320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
    Colaianni A; Chandrasekharan S; Cook-Deegan R
    Genet Med; 2010 Apr; 12(4 Suppl):S5-S14. PubMed ID: 20393311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tay-Sachs disease in persons of French-Canadian heritage in northern New England.
    Palomaki GE; Williams J; Haddow JE; Natowicz MR
    Am J Med Genet; 1995 May; 56(4):409-12. PubMed ID: 7604851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.